FDA rejects gallstone shock treatment:
This article was originally published in Clinica
The FDA rejected a premarketing approval application for a shockwave therapy device for breaking up gallstones despite a recommendation from its own advisory panel. Medstone International, the Aliso Veijo, California-based company which makes the device, said it is "deeply disappointed" with the decision and plans to respond to the agency.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.